UCB PHARMA SA
π§πͺBelgium
- Country
- π§πͺBelgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures
- First Posted Date
- 2013-04-15
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 473
- Registration Number
- NCT01832038
- Locations
- π¨π³
86019, Jinan, China
π¨π³86004, Kunming, China
π¨π³86012, Nanchang, China
Comparison of Brivaracetam Oral Tablet (10 mg, 50 mg, 75 mg and 100 mg) and Brivaracetam Injection (100 mg) in Healthy Volunteers
- First Posted Date
- 2013-02-22
- Last Posted Date
- 2013-04-15
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 25
- Registration Number
- NCT01796899
- Locations
- π³π±
1, Zuidlaren, Netherlands
Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors
Completed
- Conditions
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 1723
- Registration Number
- NCT01764321
- Locations
- π©πͺ
039, Aachen, Germany
π©πͺ017, Altenburg, Germany
π©πͺ079, Aachen, Germany
Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 24
- Registration Number
- NCT01764594
- Locations
- π§πͺ
101, Leuven, Belgium
π§π¬203, Plovidv, Bulgaria
π§π¬201, Sofia, Bulgaria
Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy
- First Posted Date
- 2012-11-16
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 26
- Registration Number
- NCT01728077
- Locations
- πΊπΈ
108, Lexington, Kentucky, United States
πΊπΈ110, Dallas, Texas, United States
πΊπΈ103, Little Rock, Arkansas, United States
A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-10-19
- Last Posted Date
- 2017-08-25
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 548
- Registration Number
- NCT01710657
- Locations
- π¨π³
86025, Shanghai, China
π¨π³86012, Nanchang, China
π¨π³86024, Wuhan, China
A Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-10-19
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 18
- Registration Number
- NCT01710670
Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine Transdermal Patch in Healthy Chinese Subjects
- First Posted Date
- 2012-08-29
- Last Posted Date
- 2012-12-04
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 24
- Registration Number
- NCT01675024
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 29
- Registration Number
- NCT01653262
- Locations
- πΊπΈ
108, Lexington, Kentucky, United States
πΊπΈ103, Little Rock, Arkansas, United States
πΊπΈ109, New York, New York, United States
Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 346
- Registration Number
- NCT01646255
- Locations
- π¨π³
Sp1037 006, Wuhan, China
π¨π³Sp1037 001, Beijing, China
π¨π³Sp1037 002, Beijing, China
Β© Copyright 2024. All Rights Reserved by MedPath